RHUMBLINE ADVISERS - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 106 filers reported holding LYELL IMMUNOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.5%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$395,165
-54.8%
268,826
-2.2%
0.00%
-100.0%
Q2 2023$874,188
+136066.4%
274,902
+1.0%
0.00%0.0%
Q1 2023$642
-29.7%
272,053
+3.4%
0.00%0.0%
Q4 2022$913
-100.0%
263,228
-1.7%
0.00%
-66.7%
Q3 2022$1,962,000
+20.5%
267,718
+7.2%
0.00%
+50.0%
Q2 2022$1,628,000
+113.1%
249,705
+65.0%
0.00%
+100.0%
Q1 2022$764,000
+324.4%
151,378
+549.5%
0.00%
Q4 2021$180,000
-28.0%
23,307
+38.0%
0.00%
Q3 2021$250,00016,8890.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$131,458,00059.13%
Apoletto Ltd 15,093,969$98,413,00027.22%
Foresite Capital Management IV, LLC 13,282,181$86,600,00023.32%
MIC Capital Management UK LLP 3,060,569$19,955,0003.90%
Alphabet Inc. 5,865,125$38,241,0002.08%
HSG Holding Ltd 3,045,997$19,860,0001.83%
Board of Trustees of The Leland Stanford Junior University 1,647,882$10,744,0000.72%
SG3 Management, LLC 600,000$3,912,0000.46%
KETTLE HILL CAPITAL MANAGEMENT, LLC 157,700$1,028,0000.26%
Artal Group S.A. 700,000$4,564,0000.24%
View complete list of LYELL IMMUNOPHARMA INC shareholders